Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Anticancer antibodies.

Jeffrey S Ross1, Karen Gray, Gary S Gray

  • 1Divisions of Molecular Medicine, Molecular Pathology, and Oncology Therapeutics, Millennium Pharmaceuticals, Cambridge, MA, USA.

American Journal of Clinical Pathology
|April 25, 2003
PubMed
Summary

Anticancer antibodies offer promising cancer treatments with potentially fewer side effects than small molecules. Antibody therapies, including those linked to radioisotopes or toxins, are expanding for various cancers.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

From Sequencing to Treatment: Operational Challenges in Translating Precision Oncology Into Clinical Practice.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same author

Neoadjuvant Sacituzumab Govitecan in Patients With Muscle-Invasive Bladder Cancer: Primary Results of the SURE-01 Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Ultra-high tumor mutation burden breast cancer: genomic profiling and real-world immunotherapy results.

NPJ breast cancer·2026
Same author

Homozygous Loss of Recombination Repair Genes and Poly ADP-Ribose Polymerase Inhibitor Benefit for Patients With Ovarian Cancer.

JCO precision oncology·2026
Same author

Genomics of <i>MTAP</i> Loss in >500,000 Solid Tumor Specimens Profiled Using Comprehensive Genomic Profiling Platforms.

JCO precision oncology·2026
Same author

Diabetic striatopathy associated with nonketotic hyperglycemia.

JCEM case reports·2026

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Anticancer antibodies like rituximab and trastuzumab demonstrate significant clinical and commercial success.
  • Antibody therapeutics are gaining interest for treating hematopoietic malignancies and solid tumors due to potential for lower toxicity and enhanced efficacy.
  • The development of antibody-based drugs is driven by their targeted action, potential for conjugation with cytotoxic agents, and compatibility with diagnostic tools.

Purpose of the Study:

  • To review the structure and antigenicity reduction techniques of anticancer therapeutic antibodies.
  • To discuss the efficacy, toxic effects, and conjugation strategies (radioisotopes, toxins) of antibody therapeutics.
  • To detail Food and Drug Administration-approved antibodies and those in clinical development.

Main Methods:

Related Experiment Videos

  • Literature review of existing and emerging anticancer antibody therapeutics.
  • Analysis of antibody structure, antigenicity, and conjugation technologies.
  • Examination of clinical data, efficacy, and toxicity profiles of antibody drugs.

Main Results:

  • Antibody therapeutics show promise for treating cancer with potentially reduced toxicity compared to small molecules.
  • Conjugation strategies are expanding the therapeutic potential of antibodies through radioisotopes and toxins.
  • Validated antibody targets and diagnostic characterization are crucial for improving drug performance.

Conclusions:

  • Anticancer antibodies are poised to play a significant role in monotherapy and combination cancer treatment strategies.
  • New radiolabeled and toxin-linked antibody products are expected to complement existing approvals.
  • Further research and development in antibody engineering and target validation will enhance their clinical utility.